Submitted by Anonymous (not verified) on 6 February 2026 - 16:12
Comments received from public consultation on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations III: Pregnant and breastfeeding women (EMA/653036/2019)
Source: